xFOREST Therapeutics Achieves a Third Milestone in Drug Discovery Collaboration with Takeda

xFOREST Therapeutics (Headquarter: Sakyo-ku, Kyoto, Japan; President and CEO: Shunichi Kashida; hereinafter, xFOREST) is pleased to announce the achievement of a 3rd milestone as drug discovery collaboration with Takeda to target RNA structures in neurological diseases. This project was initiated on September 25, 2020. As a result of this achievement, xFOREST will receive a milestone payment.

About xFOREST Therapeutics

xFOREST Therapeutics Co., Ltd. is a Kyoto-based biotechnology company engaged in the research and development of RNA-targeted small-molecule medicines. Building on its proprietary RNA structure analysis technology, xFOREST discovers selective small molecules for RNA targets that protein-first discovery cannot reach, and advances them into drug programs with partners.